EWM
SPRO icon

Executive Wealth Management’s Spero Therapeutics SPRO Stock Holding History

Executive Wealth Management’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-413
Closed -$5K – 694
2019
Q2 		$5K Hold
413
– – ﹤0.01% 726
2019
Q1 		$5K Hold
413
– – ﹤0.01% 658
2018
Q4 		$3K Buy
+413
New +$3.35K ﹤0.01% 741

Other funds holding SPRO

AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Executive Wealth Management's SPRO Position: Q3 2019 in Review

Executive Wealth Management sold out of Spero Therapeutics (SPRO) in Q3 2019, closing a stake of 413 shares — an estimated $5K sold.

Executive Wealth Management first reported a position in SPRO in Q4 2018 and held it in 3 quarters. The position peaked at $5K in Q2 2019. 59 funds tracked by Wall St. Rank hold SPRO as of Q3 2019.

  • Executive Wealth Management reported no remaining Spero Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Executive Wealth Management sold 413 Spero Therapeutics shares in Q3 2019, an estimated $5K.
  • Executive Wealth Management first reported a position in Spero Therapeutics in Q4 2018 and held it in 3 quarters.
  • Executive Wealth Management's Spero Therapeutics position peaked at $5K in Q2 2019.
  • 59 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2019.

Based on Executive Wealth Management's 13F filing for Q3 2019, filed 30 Oct 2019.